Mandi Murph

University of Georgia United States of America

Mandi Murph is a Georgia Cancer Coalition Scholar and an Assistant Professor in the College of Pharmacy at the University of Georgia in Athens, Georgia. Before coming to Georgia, Murph was a postdoctoral fellow in Systems Biology at the University of Texas M.D. Anderson Cancer Center in Houston. She won a young investigator award from the Biochemical Journal. She is an author on publications in Cancer Cell, Molecular Cancer, Journal of the National Cancer Institute, Molecular Cancer Research, PLoS ONE, Clinical Cancer Research and the Journal of Biological Chemistry. She has received grant funding from the Georgia Cancer Coalition and the National Cancer Institute, which is part of the National Institutes of Health.

3books edited

2chapters authored

Latest work with IntechOpen by Mandi Murph

Melanoma - Current Clinical Management and Future Therapeutics serves as an advanced course in melanoma or an addendum to further polish expertise. Sections of the book include a thorough introduction on epidemiology and disease, the current surgical management of melanoma and lymph node dissection, immunotherapy along with drug toxicities and emerging research topics, like RAGE and autotaxin, that have potential therapeutic applications. The chapters in this book explore the most common subtype of melanoma, cutaneous disease, as well as a rare form, acral lentiginous melanoma and even canine tumors. Experts from around the globe contributed chapters, most of which have visual illustrations to depict aspects of disease management and therapy, allowing readers to grasp the advanced concepts presented.

Go to the book

Melanoma

Edited by Mandi Murph

Books edited

By Duy Nguyen, Oanh Nguyen, Honglu Zhang, Glenn D. Prestwich and Mandi M. Murph

Part of the book: Research on Melanoma

Inhibiting Lactate Dehydrogenase A Enhances the Cytotoxicity of the Mitochondria Accumulating Antioxidant, Mitoquinone, in Melanoma Cells

By Ali A. Alshamrani, James L. Franklin, Aaron M. Beedle and Mandi M. Murph

Limited options exist for inhibitors targeted against melanoma tumors with mutation subtypes other than BRAF. We investigated the cytotoxic activity of mitoquinone (MitoQ), an antioxidant and ubiquinone derivative, on various human melanoma cell lines, alone or in combination with other agents to perturb cellular bioenergetics. This lipophilic cation crosses the cell membrane, enters and accumulates in the mitochondria where it can disrupt mitochondrial function at micromolar concentrations or act as an antioxidant to preserve membrane integrity at nanomolar concentrations. Consistent with previous studies, cells treated with 12.5 μM MitoQ show significantly reduced viability versus control treatments. Although all melanoma cells were susceptible to cytotoxicity induced by MitoQ, cells with wild-type BRAF were responsive to lower doses, compared to cells with activating mutations in BRAF. Mechanistically, the positively charged lipophilic moiety of the MitoQ induced a dose-dependent collapse of the mitochondrial membrane potential (Δψm) and significantly reduced the mitochondrial ATP production and reduced oxygen consumption rate, suggesting mitochondrial dysfunction. We also combined MitoQ with a glycolytic lactate dehydrogenase A inhibitor (FX-11) and observed an enhanced reduction in viability, but not other therapies examined. To summarize, the data suggest that FX-11 enhances the cytotoxic effects of MitoQ in cells with wild-type BRAF.

Part of the book: Human Skin Cancer, Potential Biomarkers and Therapeutic Targets

Mandi Murph

Latest work with IntechOpen by Mandi Murph

Melanoma

Books edited

Research on Melanoma

Melanoma in the Clinic

Chapters authored

Related collaborators

Yaguang Xi

Duc Do

Narayanam Rao

Stefania Staibano

Gaetano De Rosa

Massimo Mascolo

Maria Siano

Xiaobo Li

Syed Rizvi

Gennaro Ilardi